218. Alport syndrome Clinical trials / Disease details

Clinical trials : 30 / Drugs : 36 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 46

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04937907 (ClinicalTrials.gov)	September 8, 2021	17/6/2021	Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)	Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)	Alport Syndrome, X-Linked	Drug: Hydroxychloroquine Sulfate 100 milligram (mg) Tab;Drug: Benazepril hydrochloride 10 milligram (mg) Tab	Shanghai Children's Hospital	NULL	Recruiting	3 Years	18 Years	All	50	Phase 2	China
2	ChiCTR2000036799	2020-10-01	2020-08-25	Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome	Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome	Alport Syndrome	experimental group:Hydroxychloroquine + Benazepril Hydrochloridec;control group:placebo + benazepril hydrochloride;	Shanghai Children's Hospital	NULL	Pending	0	18	Both	experimental group:25;control group:25;	N/A	China
3	NCT00309257 (ClinicalTrials.gov)	January 2004	30/3/2006	Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome	Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome	Alport Syndrome	Drug: ACE I, ATA II and Statins;Drug: Benazepril , Valsartan and Fluvastatin	Mario Negri Institute for Pharmacological Research	NULL	Completed	15 Years	70 Years	Both	9	Phase 2	Italy